BIOMAT Database Logo BIOMAT Database Logo

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. 1991

R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Department of Pediatrics, University of Massachusetts Medical School, Worcester 01605.

The dipyridodiazepinone human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitor BI-RG-587 was tested for its ability to inhibit HIV-1 replication in both acutely and chronically infected cell lines. The ability of BI-RG-587 to inhibit steps in the virus replicative cycle other than reverse transcription was also assessed. BI-RG-587 was found to be a potent inhibitor of HIV-1 replication in acutely infected cells (50% inhibitory concentration [IC50] = 37.2 nM), and the sensitivity and kinetics of that inhibition was similar to the known RT inhibitor zidovudine (AZT). Even at 100x IC50, BI-RG-587 had no effect on gp120/CD4 interaction, syncytia formation, or envelope glycoprotein processing. In addition, no inhibition of viral replication or protein production was noted in a chronically infected cell line that produces viral products in an RT-independent manner. Finally, no inhibition of acute HIV-2 replication was noted, even with very high (2500x IC50 for HIV-1) concentrations of BI-RG-587. These results demonstrate that BI-RG-587 is a potent inhibitor of HIV-1 replication and that this inhibition occurs at the point of reverse transcription.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012191 Retroviridae Proteins Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein. Leukovirus Proteins,Retrovirus Proteins,Proteins, Leukovirus,Proteins, Retroviridae,Proteins, Retrovirus
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D015726 Giant Cells Multinucleated masses produced by the fusion of many cells; often associated with viral infections. In AIDS, they are induced when the envelope glycoprotein of the HIV virus binds to the CD4 antigen of uninfected neighboring T4 cells. The resulting syncytium leads to cell death and thus may account for the cytopathic effect of the virus. Giant Cells, Multinucleated,Multinucleated Giant Cells,Polykaryocytes,Syncytium,Syncytia,Cell, Giant,Cell, Multinucleated Giant,Cells, Giant,Cells, Multinucleated Giant,Giant Cell,Giant Cell, Multinucleated,Multinucleated Giant Cell,Polykaryocyte

Related Publications

R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.
March 1992, Biochemical pharmacology,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine).
January 1992, Medicinal research reviews,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.
June 1991, Nucleic acids research,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.
February 1991, Antimicrobial agents and chemotherapy,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins.
September 1994, Antiviral research,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase.
August 1991, The Journal of biological chemistry,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.
October 1995, Journal of virology,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Inhibition of human immunodeficiency virus type (HIV-1) replication by some diversely functionalized spirocyclopropyl derivatives.
May 1999, Archiv der Pharmazie,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
April 2001, Journal of virology,
R A Koup, and V J Merluzzi, and K D Hargrave, and J Adams, and K Grozinger, and R J Eckner, and J L Sullivan
Inhibition of human immunodeficiency virus type-1 (HIV-1) replication by immunor (IM28), a new analog of dehydroepiandrosterone.
January 2000, Nucleosides, nucleotides & nucleic acids,
Copied contents to your clipboard!